ArticleCardiovascular diabetology2021

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease.

Lisanne C A Smidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.